{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:21:38Z","timestamp":1785788498070,"version":"3.56.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002701","name":"Korea Ministry of Education","doi-asserted-by":"publisher","award":["202200331"],"award-info":[{"award-number":["202200331"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003398","name":"Shanxi Scholarship Council of China","doi-asserted-by":"publisher","award":["2024\\u2013079"],"award-info":[{"award-number":["2024\\u2013079"]}],"id":[{"id":"10.13039\/501100003398","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Colloids and Surfaces B: Biointerfaces"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.colsurfb.2026.115809","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:13:54Z","timestamp":1778757234000},"page":"115809","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["De Novo developing nanoplatform encapsuling \u03b1-arbutin and \u03b1-syn inhibitor for precise treatment of Parkinson's disease"],"prefix":"10.1016","volume":"266","author":[{"given":"Yan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhe","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengwu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.colsurfb.2026.115809_bib1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.colsurfb.2026.115809_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102208","article-title":"An update on new-age potential biomarkers for Parkinson's disease","volume":"94","author":"Soni","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.colsurfb.2026.115809_bib3","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.autrev.2016.07.022","article-title":"Parkinson's disease: autoimmunity and neuroinflammation","volume":"15","author":"De Virgilio","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.colsurfb.2026.115809_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13024-017-0186-8","article-title":"Post translational changes to \u03b1-synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson's disease","volume":"12","author":"Duce","year":"2017","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.colsurfb.2026.115809_bib5","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.colsurfb.2026.115809_bib6","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s00415-025-13030-2","article-title":"Global trends and projections of Parkinson's disease incidence: a 30-year analysis using GBD 2021 data","volume":"272","author":"Xu","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.colsurfb.2026.115809_bib7","doi-asserted-by":"crossref","first-page":"e080952","DOI":"10.1136\/bmj-2024-080952","article-title":"Projections for prevalence of Parkinson's disease and its driving factors in 195 countries and territories to 2050: modelling study of global burden of disease study 2021","volume":"388","author":"Su","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.colsurfb.2026.115809_bib8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","article-title":"Challenges in the diagnosis of Parkinson's disease","volume":"20","author":"Tolosa","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.colsurfb.2026.115809_bib9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000527372","article-title":"Burden of Parkinson disease in China, 1990-2019: findings from the 2019 global burden of disease study","volume":"57","author":"Zheng","year":"2023","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.colsurfb.2026.115809_bib10","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S1474-4422(20)30036-3","article-title":"Initiation of pharmacological therapy in Parkinson's disease: when, why, and how","volume":"19","author":"de Bie","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.colsurfb.2026.115809_bib11","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.2174\/1570159X15666170510143821","article-title":"Levodopa in Parkinson's disease: current status and future developments","volume":"16","author":"Tambasco","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.colsurfb.2026.115809_bib12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/npp.2011.212","article-title":"Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa","volume":"37","author":"Smith","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.colsurfb.2026.115809_bib13","doi-asserted-by":"crossref","first-page":"661","DOI":"10.20344\/amp.11978","article-title":"[Parkinson's disease: clinical review and update]","volume":"32","author":"Cabreira","year":"2019","journal-title":"Acta Med. Port."},{"key":"10.1016\/j.colsurfb.2026.115809_bib14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1227\/01.neu.0000315998.58022.55","article-title":"L-dopa-induced dyskinesia and stereotactic surgery for Parkinson's disease","volume":"62","author":"Guridi","year":"2008","journal-title":"Neurosurgery"},{"key":"10.1016\/j.colsurfb.2026.115809_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2023.105980","article-title":"The history of deep brain stimulation","volume":"121","author":"Cavallieri","year":"2024","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.colsurfb.2026.115809_bib16","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s00702-024-02863-2","article-title":"Mitochondrial dysfunction in Parkinson's disease","volume":"131","author":"Hattori","year":"2024","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.colsurfb.2026.115809_bib17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41583-023-00676-y","article-title":"Mitochondrial complex I deficiency and Parkinson disease","volume":"24","author":"Drouin-Ouellet","year":"2023","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.colsurfb.2026.115809_bib18","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1007\/s11064-018-2673-x","article-title":"Alpha-synuclein toxicity on protein quality control, mitochondria and endoplasmic reticulum","volume":"43","author":"Melo","year":"2018","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.colsurfb.2026.115809_bib19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13024-024-00756-2","article-title":"\u03b1-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson's disease","volume":"19","author":"Geibl","year":"2024","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.colsurfb.2026.115809_bib20","doi-asserted-by":"crossref","first-page":"19961","DOI":"10.1021\/acsnano.3c05011","article-title":"Engineered selenium\/human serum albumin nanoparticles for efficient targeted treatment of Parkinson's disease via oral gavage","volume":"17","author":"Xu","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.colsurfb.2026.115809_bib21","article-title":"Brain-targeted liposomes loaded with monoclonal antibodies reduce alpha-synuclein aggregation and improve behavioral symptoms in Parkinson's disease","volume":"35","author":"Sela","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.colsurfb.2026.115809_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202300758","article-title":"Ameliorating mitochondrial dysfunction of neurons by biomimetic targeting nanoparticles mediated mitochondrial biogenesis to boost the therapy of Parkinson's disease","volume":"10","author":"Zheng","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.colsurfb.2026.115809_bib23","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1021\/acs.molpharmaceut.3c01167","article-title":"Cell-penetrating peptides: promising therapeutics and drug-delivery systems for neurodegenerative diseases","volume":"21","author":"Pirhaghi","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.colsurfb.2026.115809_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/nano9030371","article-title":"Nanomaterials for drug delivery to the central nervous system","volume":"9","author":"Teleanu","year":"2019","journal-title":"Nanomaterials"},{"key":"10.1016\/j.colsurfb.2026.115809_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122680","article-title":"Intranasal delivery of liposome encapsulated flavonoids ameliorates l-DOPA induced dyskinesia in hemiparkinsonian mice","volume":"311","author":"Ahmed","year":"2024","journal-title":"Biomaterials"},{"key":"10.1016\/j.colsurfb.2026.115809_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2025.117473","article-title":"In situ dual-activated NIRF\/PA carrier-free nanoprobe for diagnosis and treatment of Parkinson's disease","volume":"282","author":"Guo","year":"2025","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/j.colsurfb.2026.115809_bib27","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6528\/abf4a9","article-title":"Hollow mesoporous polydopamine nanospheres: synthesis, biocompatibility and drug delivery","volume":"32","author":"Lin","year":"2021","journal-title":"Nanotechnology"},{"key":"10.1016\/j.colsurfb.2026.115809_bib28","first-page":"33","article-title":"Spatiotemporally targeted nanocapsules combined with mild photothermal therapy regulate the synovial microenvironment in rheumatoid arthritis","volume":"58","author":"Wu","year":"2026","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.colsurfb.2026.115809_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202207448","article-title":"Rapidly inhibiting the inflammatory cytokine storms and restoring cellular homeostasis to alleviate sepsis by blocking pyroptosis and mitochondrial apoptosis pathways","volume":"10","author":"Yan","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.colsurfb.2026.115809_bib30","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1021\/acsami.4c20358","article-title":"Efficient co-delivery of metformin and ammonia borane via a hollow mesoporous polydopamine nanogenerator for enhanced chemo-photothermal therapy against melanoma","volume":"17","author":"Lin","year":"2025","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.colsurfb.2026.115809_bib31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12017-019-08562-6","article-title":"\u03b1-arbutin protects against parkinson's disease-associated mitochondrial dysfunction in vitro and in vivo","volume":"22","author":"Ding","year":"2020","journal-title":"Neuromol. Med."},{"key":"10.1016\/j.colsurfb.2026.115809_bib32","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2174\/0125899775298987240528050110","article-title":"Arbutin's potential in neuroprotection: a promising role in mitigating neurodegenerative diseases","volume":"17","author":"Sharma","year":"2025","journal-title":"Curr. Drug Res. Rev."},{"key":"10.1016\/j.colsurfb.2026.115809_bib33","article-title":"Amelioration of behavioral and neural deficits in animal models of neurodegenerative disease by nanoformulations of curcumin and quercetin","author":"Martinez","year":"2025","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.colsurfb.2026.115809_bib34","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.biotechadv.2016.04.004","article-title":"Curcumin, mitochondrial biogenesis, and mitophagy: exploring recent data and indicating future needs","volume":"34","author":"de Oliveira","year":"2016","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.colsurfb.2026.115809_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/ph16111631","article-title":"Quercetin as a therapeutic product: evaluation of its pharmacological action and clinical applications-a review","volume":"16","author":"Mirza","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.colsurfb.2026.115809_bib36","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s40478-025-02099-5","article-title":"Anle138b mitigates post-hypoxic cognitive impairment, \u03b1-synuclein aggregation and UPR activation in drosophila melanogaster","volume":"13","author":"Fehr","year":"2025","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.colsurfb.2026.115809_bib37","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","article-title":"Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease","volume":"125","author":"Wagner","year":"2013","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.colsurfb.2026.115809_bib38","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1038\/s41467-022-32797-w","article-title":"The clinical drug candidate anle138b binds in a cavity of lipidic \u03b1-synuclein fibrils","volume":"13","author":"Antonschmidt","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.colsurfb.2026.115809_bib39","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood-brain barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.colsurfb.2026.115809_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/md21070406","article-title":"The rare marine bioactive compounds in neurological disorders and diseases: is the blood-brain barrier an obstacle or a target?","volume":"21","author":"Diao","year":"2023","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.colsurfb.2026.115809_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119491","article-title":"Nanomaterial-based blood-brain-barrier (BBB) crossing strategies","volume":"224","author":"Xie","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.colsurfb.2026.115809_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114051","article-title":"RVG29 and platelet membrane-modified pseudo-mitochondria for cascade targeting of cyclosporin a in traumatic brain injury","volume":"385","author":"Hu","year":"2025","journal-title":"J. Control Release"},{"key":"10.1016\/j.colsurfb.2026.115809_bib43","first-page":"529","article-title":"Macrophage membrane-coated nanocarriers Co-Modified by RVG29 and TPP improve brain neuronal mitochondria-targeting and therapeutic efficacy in Alzheimer's disease mice","volume":"6","author":"Han","year":"2021","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.colsurfb.2026.115809_bib44","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41392-023-01486-5","article-title":"Role of neuroinflammation in neurodegeneration development","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target Ther."}],"container-title":["Colloids and Surfaces B: Biointerfaces"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776526003978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776526003978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:27:49Z","timestamp":1785785269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0927776526003978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":44,"alternative-id":["S0927776526003978"],"URL":"https:\/\/doi.org\/10.1016\/j.colsurfb.2026.115809","relation":{},"ISSN":["0927-7765"],"issn-type":[{"value":"0927-7765","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"De Novo developing nanoplatform encapsuling \u03b1-arbutin and \u03b1-syn inhibitor for precise treatment of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Colloids and Surfaces B: Biointerfaces","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.colsurfb.2026.115809","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115809"}}